Zanubrutinib: 16 agencies, 2021–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) has been harder on zanubrutinib than on its own caseload: it refused 4 of 5 decisive submissions here (80%), against a base rate of 11% across everything it has assessed.
Assessment has run over 5.2 years, from 2021 at PBAC (Australia) to 22 Sep 2026 at ZIN (Netherlands).
PBAC (Australia) changed its position: not recommended in 2021, recommended by 2025, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for zanubrutinib.
Not every gap is a refusal: for zanubrutinib, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 44 of 58 records date from 2023 or later.
The programme is broad: 18 distinct indication wordings are recorded for zanubrutinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 58 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess zanubrutinib, in 2021; CIPM (Spain) did not open a file until 17 Dec 2025 — a wide spread of 4.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 25 of 56 dated records fall in 2023 alone.
14 of the 16 agencies here assessed zanubrutinib more than once, PHARMAC (New Zealand) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
zanubrutinib has been through 16 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for zanubrutinib reads 28 recommended, 11 restricted, 7 not recommended and 5 no benefit, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 17 May 2026 | Monoterapi for behandling av voksne pasienter med marginalsonelymfom (MSL) som har mottatt minst en tidligere anti-CD20-… | introduced | source |
| AOTMIT (Poland) | 6 Feb 2026 | programu lekowego B.79 „Leczenie chorych na przewlekłą białaczkę limfocytową lub chłoniaka z małych limfocytów B (ICD -1… | not recommended | source |
| CIPM (Spain) | 17 Dec 2025 | Indicaciones terapéuticas autorizadas: BRUKINSA en monoterapia está indicado para el tratamiento de pacientes adultos co… | financed by the SNS | source |
| NICE (England) | 10 Jul 2025 | NICE TA1081 | published appraisal | source |
| SMC (Scotland) | 13 May 2024 | In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic th… | not recommended | source |
53 further decisions for zanubrutinib, across 15 agencies, are not shown here. They include the most recent record on file, 22 Sep 2026 from ZIN (Netherlands); its outcome is in the subscriber dataset. They link to 44 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
- ruxolitinib — same ATC class L01E — Antineoplastics
Coverage: 58 decisions for zanubrutinib from 16 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.